AG-348: Additional Ph II DRIVE-PK data

Data from 32 transfusion-independent adult patients with pyruvate kinase deficiency in the open-label, international Phase II DRIVE-PK trial showed that twice-daily 50 and 300 mg oral AG-348 for up to...